EVGN vs CTVA

For growth investors, Evogene Ltd.

(EVGN) is the stronger pick with 50. 9% revenue growth year-over-year, versus 2. 9% for Corteva, Inc. (CTVA). Corteva, Inc. (CTVA) offers the better valuation at 49. 4x trailing P/E (21. 6x forward), making it the more compelling value choice. Analysts rate Corteva, Inc. (CTVA) a "Buy" — based on 37 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Corteva, Inc.

(CTVA) delivered a total return of +68. 3%, compared to -97. 9% for Evogene Ltd. (EVGN). Over 10 years, the gap is even starker: CTVA returned +186. 7% versus EVGN's -98. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Corteva, Inc.

(CTVA) is the lower-risk stock at 0. 29β versus Evogene Ltd. 's 1. 32β — meaning EVGN is approximately 351% more volatile than CTVA relative to the S&P 500. On balance sheet safety, Corteva, Inc. (CTVA) carries a lower debt/equity ratio of 11% versus 87% for Evogene Ltd. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Evogene Ltd.

(EVGN) is pulling ahead at 50. 9% versus 2. 9% for Corteva, Inc. (CTVA). On earnings-per-share growth, the picture is similar: Evogene Ltd. grew EPS 44. 7% year-over-year, compared to 23. 1% for Corteva, Inc.. Over a 3-year CAGR, EVGN leads at 109. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Corteva, Inc.

(CTVA) is the more profitable company, earning 6. 3% net margin versus -193. 7% for Evogene Ltd. — meaning it keeps 6. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CTVA leads at 15. 1% versus -255. 4% for EVGN. At the gross margin level — before operating expenses — CTVA leads at 43. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, CTVA (0.

9% yield) pays a dividend. EVGN does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Corteva, Inc.

(CTVA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 29), 0. 9% yield, +186. 7% 10Y return). Both have compounded well over 10 years (CTVA: +186. 7%, EVGN: -98. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (EVGN (Healthcare) and CTVA (Basic Materials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: EVGN is a small-cap high-growth stock; CTVA is a mid-cap quality compounder stock. CTVA pays a dividend while EVGN does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.